research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-01. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
=== May === On May 8, Janet Jackson’s Rhythm Nation 1814 was inducted into the Grammy Hall of Fame. On May 13, Clarence Carter died at the age of 90. On May 25, the American Music Awards of 2026 were held. Bruno Mars won Best R&B Song for "I Just Might", Best R&B Album for The Romantic, and Best Male R&B Artist. SZA won Best Female R&B Artist. Leon Thomas won Breakthrough R&B Artist. On May 31, Dexter Wansel died at the age of 75.
Bupa recommends oily fish, food with tryptophan such as milk, nuts, lentils, whole grain breads, cereals, pasta, soy and chocolate, dark chocolate, the Mediterranean diet overall including vegetables, fruits, whole grains, nuts and olive oil for wellbeing. The documentary 'food matters' includes claims of well-being benefits of raw foods, which has been disputed as pseudoscience.
Mammals such as lemurs and monkeys demonstrate application of chemicals similar to how humans use chemicals for pest management and medical use. These applications vary from prevention of internal and external parasites or pathogens, decrease likelihood of infection, increase reproductive function, reducing inflammation, social cues, and more. Red-fronted lemurs (Eulemur ruffrons) have evolved two pathways, preventive measure for avoiding bioaccumulation, allowing for the modification of 2-methyl-1,4-benzoquinone and 2-methoxy-3-methyl-1,4-benzoquinone a secretion of Spirostreptidae millipedes shown to inhibit certain bacterial species. Red-fronted lemurs have also been observed in rubbing the secretion on their fur similar to capuchins, this action uses benzoquinone compounds as repellent for various insects such as ticks and mosquitoes.
Sources: en.wikipedia.org
=== International hospitals and facilities === Internationally, UPMC operates a transplant hospital in Italy (ISMETT), two hospitals and two cancer centers in Ireland, a cancer center in Rome and previously helped to establish an emergency medical system in Qatar. UPMC also implemented information technology solutions and assisting with the development of cancer centers in the United Kingdom, is providing consultation services and developing a network of co-managed hospitals in China, and, with the University of Pittsburgh School of Medicine, implemented a U.S.-style resident training program in Japan. UPMC is also a partner with the University of Pittsburgh and the governments of Italy and the region of Sicily in Fondazione Ri.Med, which is building a €210 million Biomedical Research and Biotechnology Center in Carini near Palermo. In June 2019, UPMC signed a deal with the Wanda Group to develop and operate five private hospitals in major Chinese cities. The first hospital, the Chengdu Wanda-UPMC International Hospital, is expected to open in 2022.
The Bentley compounds are a class of semi-synthetic opioids that were first synthesized by K. W. Bentley by Diels-Alder reaction of thebaine with various dienophiles. The compounds are also known as thevinols, orvinols, or bridged oripavine derivatives, due to the characteristic 6,14-endo-ethano- or etheno-bridge and substitution at the 7α position. Buprenorphine and etorphine are perhaps the best known of the family, which was the first series of extremely potent μ-opioid agonists, with some compounds in the series having over many thousands of times the analgesic potency of morphine.
In 2019, NCCD became the knowledge partner for the International Solar Alliance to help foster solar energy used in cold chains in its UN member countries. Through NCCD, various myths about India's cold storage sector were rectified and it brought about a paradigm shift in policies. NCCD was awarded the Agribusiness Leadership Award in India in 2014. In 2018, in recognition of the individual contributions of then CEO of NCCD, the University of Birmingham conferred him the title of honorary Professor. Through five technical committees constituted under NCCD, various domain experts within the country are also able to contribute in the works undertaken by NCCD. These include training in cold chain operations, workshops to encourage policy level interface between decision makers in government and operators, as well as knowledge dissemination through capacity building and awareness programmes. NCCD is recognized as the nodal body for cold chain development in India and for its unique construct, as an ecosystem of public and private sector stakeholders that serves to provide the country context relevant direction for its initiatives to develop cold chain for its agricultural sector.
=== Pharmacodynamics === The mechanistic underpinnings of bemethyl's effects are not well understood, but some evidence implicate alterations in protein synthesis and glucose metabolism, in addition to antioxidant activity, as relevant mechanisms of action.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.